Previously, Kenvue and Shenzhen Nepstar have been cooperating in the over-the-counter (OTC) drug field in China for many ...

Fintel reports that on September 24, 2024, RBC Capital downgraded their outlook for Kenvue (NYSE:KVUE) from Outperform to ...

Fintel reports that on September 24, 2024, Jefferies initiated coverage of Kenvue (NYSE:KVUE) with a Buy recommendation. ...

On Monday, Kenvue Inc (KVUE) stock saw a modest uptick, ending the day at $23.02 which represents no change from the prior close of $23.02. The stock opened at $22.83 and touched a low of $22.76 ...

Analysts split on whether Kenvue's (KVUE) reinvestment in Neutrogena could lead to market share gains. Read more here.

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

RBC Capital Markets analysts downgraded Kenvue (NYSE: KVUE) stock on Tuesday, citing challenges in the company's Skin Health & Beauty segment, particularly with its Neutrogena bra ...

Four years ago, the menstrual hygiene brand launched its ‘It’s just a period’ campaign, which champions healthy period conversations amongst people who matter most to a young girl—her family. It aims ...

THE WHAT?  Kenvue has officially launched Aveeno® in 12 Central European markets, marking a significant milestone in the ...

BL/ - Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the“Company”), the maker of iconic brands such as Aveeno®, Listerine®, ...

The Latiné diversity gap in dermatology has been highlighted as an issue, because it directly affects patient health. This ...

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with ...